Dr. Logan Debord, MD

Dr. Debord practices at Cherry Creek Dermatology in Denver, Colorado.

Dr. Debord's NPI, 1104387794, was assigned on March 27, 2019. Dr. Debord graduated from Baylor College of Medicine in 2019. Dr. Debord holds Colorado license DR.0069923.

Dr. Debord's primary practice is Cherry Creek Dermatology, at 3773 E Cherry Creek North Dr, Denver, CO 80209 in Denver County. The practice phone is (303) 388-5629.

Dr. Debord's primary practice is Cherry Creek Dermatology in Denver, Colorado. The medical group on file is Aspen and Vail Dermatology. Dmand AI also links Dr. Debord to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Debord practices, 2 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Debord's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Debord is licensed in Colorado.

CMS data shows 8,447 Medicare services from Dr. Debord across 26 procedure codes in 2024, for 659 Medicare patients. Medicare paid $180,554 for them. Every service was in an office.

CMS counts 659 Medicare patients who saw Dr. Debord in 2024. The largest group is 65 to 74, with 366 patients. 69% of them have high cholesterol, and 47% have high blood pressure. 3% are also on Medicaid. Their average risk score is 0.81, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Debord's median patient age at 59, with 50% women.

In 2024, Dr. Debord wrote 635 Medicare Part D claims for 313 patients. 86% of them were for generic drugs. CMS names the drug for 462 of them, across 14 drugs with 11 or more claims each, at $248,723 in total drug cost. In 2023, CMS named 39 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 96 out of 100 for Dr. Debord for performance year 2024, reported as part of a group. Dr. Debord accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 1,255 procedures of removal of skin lesions by Dr. Debord, more than 95% of the clinicians it reports for that procedure.

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 11 papers to Dr. Debord, published from 2018 to 2020. 2019 was the busiest year, with 5. The most frequent topics are Erythema and Social Media. Dr. Debord has published most often in Cureus. Dr. Debord's most frequent co-authors are Harry Dao, MD, Tara L. Braun, MD and Viraat Mahendra Patel, MD.

CMS Open Payments shows 180 general payments to Dr. Debord from 23 drug and device companies from 2023 to 2025. Food and beverage make up the largest share, 97% of the total. Sanofi and Genzyme US Companies paid the most, $728.

Dr. Debord graduated from Baylor College of Medicine in 2019.